Monte Rosa Therapeutics has started patient dosing in its Phase 2 MODeFIRe-1 trial of MRT-2359 with apalutamide for AR mutation-positive metastatic castration-r

Monte Rosa Therapeutics has started patient dosing in its Phase 2 MODeFIRe-1 trial of MRT-2359 with apalutamide for AR mutation-positive metastatic castration-resistant prostate cancer. The study will test safety and efficacy in a high-need setting.